ValuEngine upgraded shares of Taro Pharmaceutical Industries (NYSE:TARO) from a sell rating to a hold rating in a report published on Wednesday, March 14th.
Separately, HC Wainwright started coverage on Taro Pharmaceutical Industries in a report on Monday, March 12th. They issued a buy rating and a $124.00 price objective for the company. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Taro Pharmaceutical Industries currently has a consensus rating of Hold and a consensus target price of $124.00.
Shares of Taro Pharmaceutical Industries (NYSE:TARO) traded down $0.16 during trading hours on Wednesday, hitting $100.00. The stock had a trading volume of 1,200 shares, compared to its average volume of 89,948. Taro Pharmaceutical Industries has a 1 year low of $93.01 and a 1 year high of $128.46. The company has a market capitalization of $4,009.00, a P/E ratio of 19.45 and a beta of 0.64.
Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $1.37 earnings per share for the quarter. Taro Pharmaceutical Industries had a return on equity of 11.35% and a net margin of 30.43%. The firm had revenue of $155.46 million during the quarter. sell-side analysts anticipate that Taro Pharmaceutical Industries will post 5.28 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TARO. Arrowstreet Capital Limited Partnership bought a new stake in Taro Pharmaceutical Industries in the 4th quarter worth about $11,093,000. Millennium Management LLC bought a new stake in Taro Pharmaceutical Industries in the 4th quarter worth about $10,688,000. Acadian Asset Management LLC grew its stake in shares of Taro Pharmaceutical Industries by 154.4% during the 4th quarter. Acadian Asset Management LLC now owns 109,257 shares of the company’s stock valued at $11,439,000 after purchasing an additional 66,306 shares during the period. Brandes Investment Partners LP grew its stake in shares of Taro Pharmaceutical Industries by 225.9% during the 4th quarter. Brandes Investment Partners LP now owns 71,163 shares of the company’s stock valued at $7,451,000 after purchasing an additional 49,327 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Taro Pharmaceutical Industries by 24.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 222,310 shares of the company’s stock valued at $25,051,000 after purchasing an additional 43,918 shares during the period. Institutional investors own 12.25% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Taro Pharmaceutical Industries (NYSE:TARO) Stock Rating Upgraded by ValuEngine” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://ledgergazette.com/2018/03/22/taro-pharmaceutical-industries-taro-lifted-to-hold-at-valuengine.html.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.